6 completed. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 1 | Completed 1 |
Follow Serenity Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4 SER120 750 ng, SER120 1500 ng, Placebo - Nocturia | Phase 3 | Completed | Serenity Pharmaceuticals, Inc. | 810 | 2013-08-01 | 2020-11-09 |
| Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia SER120 (750 ng/day), SER120 (1000 ng/day), SER120 (1500 ng/day) - Nocturia | Phase 2 / Phase 3 | Completed | Serenity Pharmaceuticals, Inc. | 750 | 2011-05-01 | 2020-10-08 |
| Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia SER120 Nasal Spray 500 ng/day, SER120 nasal spray 750 ng/day - Nocturia | Phase 3 | Completed | Serenity Pharmaceuticals, Inc. | 32 | 2010-04-01 | 2020-11-17 |
| Long Term Safety Assessment of SER120 in Patients With Nocturia SER120 - Nocturia | Phase 3 | Completed | Serenity Pharmaceuticals, Inc. | 376 | 2009-08-01 | 2021-01-20 |
| Treatment of Patients With Nocturia (Non-PK Study) SER120, Placebo - Nocturia | Phase 3 | Completed | Serenity Pharmaceuticals, Inc. | 326 | 2009-06-01 | 2020-10-22 |
| Treatment of Patients With Nocturia SER120, Placebo - Nocturia | Phase 3 | Completed | Serenity Pharmaceuticals, Inc. | 301 | 2009-06-01 | 2020-09-18 |
Nocturia (6)
United States (6)